New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Check below for free stories on CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
September 2, 2014
09:57 EDTSTJSt. Jude Medical announces primary outcome two-year data from FAME 2 trial
Subscribe for More Information
08:34 EDTHUMHumana to reaffirm FY14 EPS view $7.25-$7.75, consensus $7.73
Members of Humana Inc.’s senior management team are scheduled to meet with investors at various times between September 3 and the end of the month. During such meetings, Humana’s management expects to reaffirm its guidance of $7.25-$7.75 in diluted EPS for the year ending December 31, 2014. This EPS guidance is consistent with that issued in Humana’s current report on Form 8-K filed with the U.S. SEC on July 30 and subsequently reiterated in investor presentations posted to the Investor Relations section of its web site.
08:07 EDTBSXBoston Scientific closed agreement to acquire Interventional business of Bayer
Boston Scientific (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer (BAYRY). The addition of the Bayer Interventional strong commercial organization and innovative technologies supports the Boston Scientific strategy to provide a comprehensive portfolio of solutions to treat peripheral vascular disease. The transaction includes the leading AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in an innovative and fast-growing therapy to remove plaque and thrombi from diseased arteries.
07:10 EDTCNCCentene to create up to 200 jobs in new processing center in Ferguson, Missouri
Subscribe for More Information
06:36 EDTMDTMedtronic, AbbVie reimburse executives for inversion-triggered taxes, WSJ says
Subscribe for More Information
September 1, 2014
15:59 EDTSTJSt. Jude Medical announces new Fractional Flow Reserve trial
Subscribe for More Information
August 31, 2014
14:18 EDTBSXBoston Scientific NECTAR-HF trial did not meet primary efficacy endpoint
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure, NECTAR-HF, clinical trial, the first and only randomized sham-controlled clinical trial investigating vagus nerve stimulation, VNS, for the treatment of heart failure patients. Faiez Zannad, M.D., Ph.D., Professor of Therapeutics and Cardiology and Director of the Clinical Investigation Center at the Institut National de la Sante et de la Recherche Medicale presented the results at the 2014 European Society of Cardiology Congress in Barcelona, Spain. The results will also be published in the European Heart Journal. The study evaluated 96 New York Heart Association,NYHA, Class II-III patients with heart failure and an ejection fraction of less than 35%. All patients continued receiving optimal medical treatment for heart failure, but were randomized 2:1 to treatment or sham, respectively. The trial did not meet the pre-specified six month primary efficacy endpoint of a reduction in left ventricular end systolic diameter as assessed by a blinded echocardiography core laboratory. Quality of life metrics demonstrated significant symptomatic improvement despite the lack of a significant effect on primary and secondary endpoint measures of cardiac remodeling and functional capacity in HF patients. "The careful design and execution of NECTAR-HF has resulted in high quality data that will improve the understanding of the role of VNS in the treatment of patients with heart failure," said Prof. Zannad, NECTAR-HF Principal Investigator. "Although patients receiving therapy reported feeling better as assessed by quality of life questionnaires, the application of VNS failed to reveal clear benefit when compared to sham, because the effect of therapy was no better than sham on echocardiography derived measurements. Inclusion of an appropriate control group is crucial, and a randomized study like NECTAR-HF should be the benchmark for future studies of novel device therapies for the treatment of heart failure." After six months of randomization, control patients begin to receive active therapy. All patients are followed through 18 months for the safety endpoint.
14:00 EDTCIFBR Capital to hold a conference
Healthcare Conference to be held in Boston on September 3.
13:53 EDTSTJSt. Jude Medical Quartet quadripolar lead performed better than bipolar leads
Subscribe for More Information
12:50 EDTMDTEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
17:06 EDTBSXBoston Scientific reports results from multinational stent study
A Boston Scientific prospective, multinational study on stent removability and preliminary long term stricture resolution of benign biliary strictures has been published in the August issue of the peer-reviewed journal, Gastroenterology. The multinational study is being conducted in 11 countries and five continents, and examines removal of fully covered self-expanding metal stents after extended indwell. The 187-patient study was designed to evaluate the ability to remove the Fully Covered WallFlex Biliary RX Stent after extended indwell and to determine treatment success of biliary obstructions resulting from benign biliary strictures. Data highlights: The WallFlex Biliary RX Stents were successfully removed by endoscopy from all 155 patients in whom this procedure was attempted. Stricture resolution without the need to restent at the time of stent removal was successful in approximately 75% of patients. Approximately 85% of these patients remained stricture-free after a mean follow-up of 20 months. The study results demonstrate that FCSEMS are an effective treatment alternative to plastic stents, and may significantly reduce the need for multiple sequential Endoscopic Retrograde Cholangiopancreatogram stent exchanges and the associated complications and costs.
August 28, 2014
17:42 EDTMDT, BSX, STJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
09:05 EDTMDTMedtronic receives clearance for Shilla Growth Guidance System
Subscribe for More Information
08:08 EDTCNCCentene's Missouri subsidiary receives accreditation rating by NCQA
Subscribe for More Information
August 27, 2014
19:16 EDTCNCAviv REIT to replace Centene in S&P 600 as of 9/3 close
Subscribe for More Information
19:15 EDTCNCCentene to replace MICROS in S&P 400 as of 9/3 close
11:41 EDTMDTMedtronic management to meet with Jefferies
Subscribe for More Information
10:05 EDTMDTMedtronic announces first implants in AdaptResponse CRT clinical trial
Medtronic announced the first implants in a clinical trial that will compare patient and healthcare system outcomes in heart failure patients who have cardiac resynchronization therapy devices with the AdaptivCRT feature enabled versus patients receiving standard CRT. The AdaptResponse trial will assess the superiority of the AdaptivCRT algorithm, which preserves normal heart rhythms and automatically adjusts to patients' needs to customize therapy. It is expected to enroll approximately 3K patients worldwide. The primary endpoint of the AdaptResponse trial is a combination of all-cause mortality and the rate of medical intervention for worsening heart failure. The trial also will examine the incidence of atrial fibrillation in enrolled patients. Other secondary endpoints will assess patient quality of life measures as well as cost-effectiveness of CRT devices with the AdaptivCRT feature relative to standard CRT. Patients will receive a CRT-pacemaker or CRT-defibrillator equipped with the AdaptivCRT algorithm, and will be randomized 1:1 to either treatment or control groups. Patients will be followed at three and six months after randomization, and then every six months until trial closure.
05:40 EDTMDTMedtronic sees impact of NGC Medical acquisition neutral to FY15 earnings
Subscribe for More Information
August 26, 2014
19:33 EDTMDTCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
16:29 EDTSTJSt. Jude Medical resolves FDA warning letter for Plano facility
Subscribe for More Information
08:30 EDTHNTHealth Net Federal Services receives URAC disease management reaccreditation
Subscribe for More Information
05:54 EDTMDTMedtronic acquires Sapiens SBS for $200M
Subscribe for More Information
August 25, 2014
11:09 EDTBSXFDA confirms third Watchman panel for Boston Scientific, says Wells Fargo
Subscribe for More Information
10:03 EDTMDTMedtronic announces FDA approval of Viva CRT-P for heart failure or AV block
Subscribe for More Information
August 24, 2014
21:53 EDTUNHNational Association of Chain Drug Stores to hold an expo
2014 NACDS Total Store Expo to be held in Boston on August 23-25.
August 21, 2014
16:09 EDTCICigna expects to reaffirm FY14 income guidance of $1.94B-$2.0B
Subscribe for More Information
August 20, 2014
08:47 EDTMDTMedtronic valuation attractive, says Morgan Stanley
Morgan Stanley said Medtronic's (MDT) valuation is attractive given pipeline execution, margin growth and shareholder returns, and expectations for the Covidien (COV) deal to go through. Shares are Overweight rated
08:31 EDTHNTCognizant deal with Health Net has encouraging read through, says Cowen
Cowen noted Cognizant (CTSH) shareholders were concerned over its deal with Health Net (HNT) but noted management feels the deal is a true partnership. The firm feels management's positive comments are encouraging and address the execution and profitability concerns of shareholders. Shares of Cognizant are Outperform rated with a $50 price target.
07:18 EDTMDTMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use